In its annual report analyzing the biopharmaceutical sector’s rate of return on innovation, Deloitte says the industry is expected to continue seeing increasing ROI, but that continuing on that positive path will require companies to be “brave and bold.” It describes such an approach as one that pursues originality, such as novel mechanisms of action and unmet medical needs, rather than trying to do what has worked well for competitors.
Deloitte Sees Rising Industry ROI, But Challenge In Sustaining It
Projected return on investment for the 20 pharmas with the highest R&D spend is expected to rise for the second straight year, Deloitte says. How to get there is less clear.
More from Strategy
More from R&D
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.